It has been suggested that endogenously synthesized maspin could be a therapeutic target agent even for triple negative estrogen and progesterone receptors statuses in breast cancer (6), where the prognosis of the condition has been reported to be worst compared to that of the double negative estrogen receptors statuses (7). Here, SERPINB5 is linked to breast cancer.